Volume 60, Issue 6 pp. 643-644

Editorial

Evidence of persistent improvements with long-term subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy

Carolina Barnett MD, PhD,

Corresponding Author

Carolina Barnett MD, PhD

[email protected]

orcid.org/0000-0001-5546-0221

Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Division of Neurology, Department of Medicine, University Health Network, Toronto, Ontario, Canada

Ellen and Martin Prossermann Centre for Neuromuscular Diseases, Toronto General Hospital, Toronto, Ontario, Canada

Correspondence

Carolina Barnett, 200 Elizabeth St, 5EC Room 334, Toronto, ON M5G 2C4, Canada.

Email: [email protected]

Search for more papers by this author

Hamid Sadeghian MD, FRCP,

Hamid Sadeghian MD, FRCP

Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Division of Neurology, Department of Medicine, University Health Network, Toronto, Ontario, Canada

Ellen and Martin Prossermann Centre for Neuromuscular Diseases, Toronto General Hospital, Toronto, Ontario, Canada

Search for more papers by this author

Carolina Barnett MD, PhD,

Corresponding Author

Carolina Barnett MD, PhD

[email protected]

orcid.org/0000-0001-5546-0221

Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Division of Neurology, Department of Medicine, University Health Network, Toronto, Ontario, Canada

Ellen and Martin Prossermann Centre for Neuromuscular Diseases, Toronto General Hospital, Toronto, Ontario, Canada

Correspondence

Carolina Barnett, 200 Elizabeth St, 5EC Room 334, Toronto, ON M5G 2C4, Canada.

Email: [email protected]

Search for more papers by this author

Hamid Sadeghian MD, FRCP,

Hamid Sadeghian MD, FRCP

Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Division of Neurology, Department of Medicine, University Health Network, Toronto, Ontario, Canada

Ellen and Martin Prossermann Centre for Neuromuscular Diseases, Toronto General Hospital, Toronto, Ontario, Canada

Search for more papers by this author

First published: 10 October 2019

https://doi.org/10.1002/mus.26734

Citations: 1

See editorial on pages 662–667 in this issue.

Share a link

Email
Wechat
Bluesky

Abstract

See article on pages 662–667 in this issue.

CONFLICT OF INTEREST

Carolina Barnett has served as a consultant for Alexion, Akcea and Takeda; she has received research grants from Grifols and Octapharma. Hamid Sadeghian reports no conflicts of interest.

REFERENCES

1Vermeulen M, Van der Meché FGA, Speelman JD, Weber A, Busch HFM. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci. 1985; 70: 317-326.
10.1016/0022-510X(85)90173-X
CAS PubMed Web of Science® Google Scholar
2van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018; 17: 35-46.
10.1016/S1474-4422(17)30378-2
PubMed Web of Science® Google Scholar
3Hughes RAC, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008; 7: 136-144.
10.1016/S1474-4422(07)70329-0
CAS PubMed Web of Science® Google Scholar
4 RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 2009; 8: 158-164.
10.1016/S1474-4422(08)70299-0
CAS PubMed Web of Science® Google Scholar
5Kerr J, Quinti I, Eibl M, et al. Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Front Immunol. 2014; 5: 629.
10.3389/fimmu.2014.00629
PubMed Web of Science® Google Scholar
6Cirillo G, Todisco V, Ricciardi D, Tedeschi G. Clinical-neurophysiological correlations in CIDP patients treated with subcutaneous immunoglobulin. Muscle Nerve. Published online: August. 2019; 15. https://doi.org/10.1002/mus.26669.
Google Scholar
7van Schaik IN, Mielke O, Bril V, et al. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm. 2019; 6:e590.
10.1212/NXI.0000000000000590
PubMed Web of Science® Google Scholar
8Bril V, Banach M, Dalakas MC, et al. Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve. 2010; 42: 492-497.
10.1002/mus.21733
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume60, Issue6

December 2019

Pages 643-644

Evidence of persistent improvements with long-term subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy

Abstract

CONFLICT OF INTEREST

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Evidence of persistent improvements with long-term subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy

Abstract

CONFLICT OF INTEREST

REFERENCES

Citing Literature

References

Related

Information